Nektar Therapeutics (NASDAQ:NKTR) Director Jeffrey Robert Ajer Sells 3,250 Shares of Stock

Share on StockTwits

Nektar Therapeutics (NASDAQ:NKTR) Director Jeffrey Robert Ajer sold 3,250 shares of the firm’s stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $17.25, for a total transaction of $56,062.50. Following the transaction, the director now owns 25,975 shares of the company’s stock, valued at approximately $448,068.75. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Jeffrey Robert Ajer also recently made the following trade(s):

  • On Monday, September 21st, Jeffrey Robert Ajer sold 2,250 shares of Nektar Therapeutics stock. The shares were sold at an average price of $19.74, for a total transaction of $44,415.00.

NASDAQ NKTR opened at $16.59 on Thursday. The company has a 50 day simple moving average of $19.16 and a 200-day simple moving average of $20.49. The firm has a market capitalization of $2.97 billion, a price-to-earnings ratio of -6.83 and a beta of 1.77. Nektar Therapeutics has a 52-week low of $13.63 and a 52-week high of $28.60.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.24. The business had revenue of $48.85 million during the quarter, compared to analyst estimates of $22.76 million. Nektar Therapeutics had a negative net margin of 264.38% and a negative return on equity of 28.23%. The firm’s revenue was up 109.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.63) earnings per share. As a group, equities research analysts predict that Nektar Therapeutics will post -2.62 EPS for the current fiscal year.

Several equities analysts have recently weighed in on the stock. Cfra lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, June 10th. JPMorgan Chase & Co. started coverage on shares of Nektar Therapeutics in a research report on Monday, September 14th. They set a “neutral” rating and a $26.00 price objective for the company. BidaskClub raised shares of Nektar Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 17th. SVB Leerink reduced their price objective on shares of Nektar Therapeutics from $18.00 to $17.00 and set a “market perform” rating for the company in a research note on Friday, August 14th. Finally, Oppenheimer reaffirmed a “hold” rating and set a $25.00 price objective on shares of Nektar Therapeutics in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $30.50.

A number of institutional investors and hedge funds have recently modified their holdings of NKTR. State Street Corp raised its position in Nektar Therapeutics by 1.8% during the first quarter. State Street Corp now owns 4,631,555 shares of the biopharmaceutical company’s stock valued at $82,673,000 after acquiring an additional 81,450 shares in the last quarter. Victory Capital Management Inc. raised its position in Nektar Therapeutics by 108.0% during the first quarter. Victory Capital Management Inc. now owns 46,487 shares of the biopharmaceutical company’s stock valued at $830,000 after acquiring an additional 24,138 shares in the last quarter. Flagship Harbor Advisors LLC raised its position in Nektar Therapeutics by 47.8% during the first quarter. Flagship Harbor Advisors LLC now owns 7,070 shares of the biopharmaceutical company’s stock valued at $126,000 after acquiring an additional 2,285 shares in the last quarter. US Bancorp DE raised its position in Nektar Therapeutics by 0.6% during the first quarter. US Bancorp DE now owns 88,121 shares of the biopharmaceutical company’s stock valued at $1,573,000 after acquiring an additional 507 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in Nektar Therapeutics during the first quarter valued at approximately $201,000. 96.43% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Recommended Story: What does EPS mean?

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Aphria  vs. Its Competitors Head to Head Review
Aphria vs. Its Competitors Head to Head Review
Nektar Therapeutics  Director Jeffrey Robert Ajer Sells 3,250 Shares of Stock
Nektar Therapeutics Director Jeffrey Robert Ajer Sells 3,250 Shares of Stock
Two Sigma Advisers LP Increases Stake in RLI Corp
Two Sigma Advisers LP Increases Stake in RLI Corp
Cupid  Posts Quarterly  Earnings Results
Cupid Posts Quarterly Earnings Results
Cupid  Announces Quarterly  Earnings Results
Cupid Announces Quarterly Earnings Results
Philip Bowman Purchases 50,000 Shares of Kathmandu Holdings Ltd  Stock
Philip Bowman Purchases 50,000 Shares of Kathmandu Holdings Ltd Stock


 
© 2006-2020 Zolmax.